

Supplemental Table S1. Baseline Characteristics According to Treatment Modalities

Characteristic	ATD group (n=4,491)	RIA group (n=102)	P value
Age, yr	48 (40–56)	40.5 (33–48)	<0.001
Sex			0.001
Male	1,556 (34.6)	51 (50.0)	
Female	2,935 (65.3)	51 (50.00)	
Smoking			0.001
Never smoker	3,058 (68.1)	56 (54.9)	
Ex-smoker	579 (12.9)	11 (10.8)	
Current smoker	854 (19.0)	35 (34.3)	
Heavy alcohol consumption	128 (2.8)	0	0.118
Regular exercise	1,056 (23.5)	24 (23.5)	0.997
Body mass index, kg/m ²	23.3±3.1	24.0±3.1	0.025
Systolic BP, mm Hg	121.1±14.6	118.3±13.8	0.051
Diastolic BP, mm Hg	75.0±9.5	74.0±9.4	0.334
Total cholesterol, mg/dL	190.6±35.8	187.3±36.9	0.351
HDL-C, mg/dL	57.5±13.6	57.2±13.1	0.811
LDL-C, mg/dL	111.4±35.5	110.3±34.5	0.764
Fasting glucose, mg/dL	92.9±12.3	91.9±13.5	0.403
Comorbidities			
Hypertension	255 (5.7)	2 (2.0)	0.106
Dyslipidemia	638 (14.2)	9 (8.8)	0.122
Duration of ATD treatment, yr ^a	3.7±0.8	4.7±2.2	<0.001
Antithyroid drugs ^b			
Methimazole	3,147 (70.1)	93 (91.2)	<0.001
Carbimazole	532 (11.8)	12 (11.8)	0.98
PTU	3,220 (71.7)	60 (58.5)	0.004

Values are expressed as median (interquartile range), number (%), or mean±standard deviation.

ATD, antithyroid drug; RIA, radioactive iodine ablation; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PTU, propylthiouracil.

^aFor the RIA group, the duration was calculated from the initiation of antithyroid drug to the date of ablation; ^bThe frequency of drug use was calculated in duplicate when more than one type of drug was used in one patient.